These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 28043128

  • 1. Formulation and Evaluation of Anisamide-Targeted Amphiphilic Cyclodextrin Nanoparticles To Promote Therapeutic Gene Silencing in a 3D Prostate Cancer Bone Metastases Model.
    Evans JC, Malhotra M, Fitzgerald KA, Guo J, Cronin MF, Curtin CM, O'Brien FJ, Darcy R, O'Driscoll CM.
    Mol Pharm; 2017 Jan 03; 14(1):42-52. PubMed ID: 28043128
    [Abstract] [Full Text] [Related]

  • 2. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor.
    Fitzgerald KA, Malhotra M, Gooding M, Sallas F, Evans JC, Darcy R, O'Driscoll CM.
    Int J Pharm; 2016 Feb 29; 499(1-2):131-145. PubMed ID: 26721726
    [Abstract] [Full Text] [Related]

  • 3. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
    Guo J, Ogier JR, Desgranges S, Darcy R, O'Driscoll C.
    Biomaterials; 2012 Nov 29; 33(31):7775-84. PubMed ID: 22828585
    [Abstract] [Full Text] [Related]

  • 4. Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis.
    Fitzgerald KA, Guo J, Raftery RM, Castaño IM, Curtin CM, Gooding M, Darcy R, O' Brien FJ, O' Driscoll CM.
    Int J Pharm; 2016 Sep 25; 511(2):1058-69. PubMed ID: 27492023
    [Abstract] [Full Text] [Related]

  • 5. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
    Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, O'Brien FJ, O'Driscoll CM.
    Biomaterials; 2015 Oct 25; 66():53-66. PubMed ID: 26196533
    [Abstract] [Full Text] [Related]

  • 6. Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours.
    Evans JC, Malhotra M, Sweeney K, Darcy R, Nelson CC, Hollier BG, O'Driscoll CM.
    Int J Pharm; 2017 Oct 30; 532(1):511-518. PubMed ID: 28916296
    [Abstract] [Full Text] [Related]

  • 7. Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo.
    Evans JC, Malhotra M, Guo J, O'Shea JP, Hanrahan K, O'Neill A, Landry WD, Griffin BT, Darcy R, Watson RW, O'Driscoll CM.
    Nanomedicine; 2016 Nov 30; 12(8):2341-2351. PubMed ID: 27389146
    [Abstract] [Full Text] [Related]

  • 8. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J.
    Eur J Pharm Biopharm; 2019 Apr 30; 137():56-67. PubMed ID: 30779980
    [Abstract] [Full Text] [Related]

  • 9. Cyclodextrin-siRNA conjugates as versatile gene silencing agents.
    Malhotra M, Gooding M, Evans JC, O'Driscoll D, Darcy R, O'Driscoll CM.
    Eur J Pharm Sci; 2018 Mar 01; 114():30-37. PubMed ID: 29191522
    [Abstract] [Full Text] [Related]

  • 10. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
    Guo J, O'Driscoll CM, Holmes JD, Rahme K.
    Int J Pharm; 2016 Jul 25; 509(1-2):16-27. PubMed ID: 27188645
    [Abstract] [Full Text] [Related]

  • 11. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J, Cheng WP, Gu J, Ding C, Qu X, Yang Z, O'Driscoll C.
    Eur J Pharm Sci; 2012 Apr 11; 45(5):521-32. PubMed ID: 22186295
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ, Xiong MH, Shu XT, Tang RZ, Wang J.
    Mol Pharm; 2012 Oct 01; 9(10):2863-74. PubMed ID: 22924580
    [Abstract] [Full Text] [Related]

  • 13. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
    Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP.
    J Nanobiotechnology; 2021 Mar 08; 19(1):71. PubMed ID: 33685469
    [Abstract] [Full Text] [Related]

  • 14. Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer - synthesis, physicochemical characterisation and in vitro evaluation.
    Fitzgerald KA, Rahme K, Guo J, Holmes JD, O'Driscoll CM.
    J Mater Chem B; 2016 Apr 07; 4(13):2242-2252. PubMed ID: 32263220
    [Abstract] [Full Text] [Related]

  • 15. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD, Huang L.
    Mol Pharm; 2006 Apr 07; 3(5):579-88. PubMed ID: 17009857
    [Abstract] [Full Text] [Related]

  • 16. Silencing of the metastasis-linked gene, AEG-1, using siRNA-loaded cholamine surface-modified gelatin nanoparticles in the breast carcinoma cell line MCF-7.
    Abozeid SM, Hathout RM, Abou-Aisha K.
    Colloids Surf B Biointerfaces; 2016 Sep 01; 145():607-616. PubMed ID: 27285732
    [Abstract] [Full Text] [Related]

  • 17. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y, Cronin MF, Mendonça MCP, Guo J, O'Driscoll CM.
    Eur J Pharm Sci; 2023 Jun 01; 185():106427. PubMed ID: 36948408
    [Abstract] [Full Text] [Related]

  • 18. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
    Jin F, Qu X, Fan Q, Wang L, Tang T, Hao Y, Dai K.
    Mol Med Rep; 2013 Nov 01; 8(5):1486-92. PubMed ID: 24064566
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
    Hao Z, Fan W, Hao J, Wu X, Zeng GQ, Zhang LJ, Nie SF, Wang XD.
    Drug Deliv; 2016 Nov 01; 23(3):874-81. PubMed ID: 24892627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.